Clinical trial
Identifying Genetic Predictors of Durable Clinical Benefit to Pembrolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) Alone and in Combination With Chemotherapy.
NCT02710396 is registered in ClinicalTrials.gov with Columbia University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Identifying Genetic Predictors of Durable Clinical Benefit to Pembrolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) Alone and in Combination With Chemotherapy.
- Lead sponsor
- Columbia University
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- May 31, 2016
- Completion date
- March 10, 2021
- Enrollment
- 19 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.